Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Cabel - Zenith was spun off from RVX in 2013 , shares a lab and some management with RVX. Their drug targets are also epigenetic drugs although more focused on oncology.
For what the CEO said about a possible deal please revue the 2018 AGM presentation and Q&A and read all posts on the Zenith board since about June 2018.
